The use of fibrinolysis inhibitors in cardiac surgery with cardiopulmonary bypass (literature review)
Open Access
- 26 August 2024
- journal article
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Messenger of ANESTHESIOLOGY AND RESUSCITATION
- Vol. 21 (4) , 92-103
Abstract
In cardiac surgery with cardiopulmonary bypass (CPB) is a common complication. The incidence of this complication in cardiac surgery patients is estimated at about 10%. For this reason, the introduction of a patient blood management (PBM) in cardiac surgery is extremely relevant. Antifibrinolytic therapy is a key pharmacological tool of a multimodal PBM in cardiac surgery with CPB. The use of antifibrinolytics (tranexamic acid (TXA) and epsilon aminocaproic acid (EACA)) is standard practice in complex cardiac surgery with CPB. However, there is currently ongoing discussion regarding the search for the optimal dose of EACA and TXA to achieve an effective concentration in blood plasma in order to inhibit fibrinolysis with the minimization of adverse events. The use of aprotinin has a number of potential advantages, but its use in routine clinical practice is significantly limited. This review presents modern approaches to antifibrinolytic therapy, examines the mechanisms of action of the main drugs, highlights the side effects associated with the use of antifibrinolytic agents.Keywords
This publication has 49 references indexed in Scilit:
- Cost Analysis of Aprotinin Reintroduction in French Cardiac Surgery Centres: A Real-World Data-Based AnalysisAdvances in Therapy, 2023
- A review of European guidelines for patient blood management with a particular emphasis on antifibrinolytic drug administration for cardiac surgeryJournal of Clinical Anesthesia, 2022
- Bleeding After Cardiac Surgery Is Associated With an Increase in the Total Cost of the Hospital StayThe Annals of Thoracic Surgery, 2020
- Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trialThe Lancet, 2019
- Benchmarking the use of blood products in cardiac surgery to stimulate awareness of transfusion behaviourNetherlands Heart Journal, 2016
- Increased perioperative mortality following aprotinin withdrawal: a real-world analysis of blood management strategies in adult cardiac surgeryIntensive Care Medicine, 2013
- Predictors and Outcomes of Seizures After Cardiac Surgery: A Multivariable Analysis of 2,578 PatientsThe Annals of Thoracic Surgery, 2011
- Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion2007
- A Double-Blind, Placebo-Controlled Trial of Epsilon-Aminocaproic Acid for Reducing Blood Loss in Coronary Artery Bypass Grafting SurgeryJournal of the American College of Surgeons, 2006
- Activation of Coagulation and Fibrinolysis During Cardiothoracic OperationsThe Annals of Thoracic Surgery, 1998